STOCK TITAN

Eastman Chem Co Financials

EMN
FY2025 annual
Revenue $8.8B -6.7% YoY
Net Income $474.0M -47.6% YoY
EPS (Diluted) $4.10 -46.5% YoY
Free Cash Flow $424.0M -38.4% YoY
Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE December

Eastman Chem Co (EMN) reported $8.8B in revenue for fiscal year 2025, down 6.7% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI EMN FY2025

Eastman's cash generation is still intact, but margin compression and inventory-heavy working capital sharply reduce flexibility.

In FY2025, operating cash flow was $970M against net income of $474M, so cash generation held up better than the earnings line suggests. But $546M of capex cut that to free cash flow of $424M, showing that this business remains meaningfully capital-consuming even in a softer year. Dividends of $381M consumed most of that remaining cash, leaving a much smaller buffer for optional uses.

Across FY2023-FY2025, revenue softness coincided with inventory staying near $2.0B while accounts receivable fell to $737M. That mix says the cash drag is more about product sitting in the system than customers delaying payment, which is why a modest sales decline can pressure cash more than the income statement alone implies.

The quieter strength is the balance-sheet posture: debt-to-equity improved to 0.7x while the current ratio stayed at 1.4x in FY2025. At the same time, net margin fell to 5.4% from 9.7% in FY2024, so the stress showed up in profitability far more than in solvency.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 27 / 100
Financial Health Score 27/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Eastman Chem Co's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
0

Not available for Eastman Chem Co, and counted as zero in the overall score.

Growth
23

Eastman Chem Co's revenue declined 6.7% year-over-year, from $9.4B to $8.8B. This contraction results in a growth score of 23/100.

Leverage
53

Eastman Chem Co has a moderate D/E ratio of 0.70. This balance of debt and equity financing earns a leverage score of 53/100.

Liquidity
36

Eastman Chem Co's current ratio of 1.37 indicates adequate short-term liquidity, earning a score of 36/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow
51

Eastman Chem Co has a free cash flow margin of 4.8%, earning a moderate score of 51/100. The company generates positive cash flow after capital investments, but with room for improvement.

Returns
0

Not available for Eastman Chem Co, and counted as zero in the overall score.

Piotroski F-Score Neutral
5/9

Eastman Chem Co passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality Cash-Backed
2.05x

For every $1 of reported earnings, Eastman Chem Co generates $2.05 in operating cash flow ($970.0M OCF vs $474.0M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$8.8B
YoY-6.7%
5Y CAGR+0.7%
10Y CAGR-1.0%

Eastman Chem Co generated $8.8B in revenue in fiscal year 2025. This represents a decrease of 6.7% from the prior year.

Net Income
$474.0M
YoY-47.6%
5Y CAGR-0.2%
10Y CAGR-5.7%

Eastman Chem Co reported $474.0M in net income in fiscal year 2025. This represents a decrease of 47.6% from the prior year.

EPS (Diluted)
$4.10
YoY-46.5%
5Y CAGR+3.2%
10Y CAGR-3.2%

Eastman Chem Co earned $4.10 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 46.5% from the prior year.

EBITDA

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow
$424.0M
YoY-38.4%
5Y CAGR-16.9%
10Y CAGR-8.0%

Eastman Chem Co generated $424.0M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 38.4% from the prior year.

Cash & Debt
$566.0M
YoY-32.4%
5Y CAGR+0.1%
10Y CAGR+6.8%

Eastman Chem Co held $566.0M in cash against $4.2B in long-term debt as of fiscal year 2025.

Dividends Per Share
$3.33
YoY+2.1%
5Y CAGR+4.5%
10Y CAGR+7.2%

Eastman Chem Co paid $3.33 per share in dividends in fiscal year 2025. This represents an increase of 2.1% from the prior year.

Shares Outstanding
114M
YoY-0.9%
5Y CAGR-3.4%
10Y CAGR-2.6%

Eastman Chem Co had 114M shares outstanding in fiscal year 2025. This represents a decrease of 0.9% from the prior year.

Margins & Returns

Gross Margin
21.1%
YoY-3.3pp
5Y CAGR-2.2pp
10Y CAGR-5.7pp

Eastman Chem Co's gross margin was 21.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 3.3 percentage points from the prior year.

Net Margin
5.4%
YoY-4.2pp
5Y CAGR-0.2pp
10Y CAGR-3.4pp

Eastman Chem Co's net profit margin was 5.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 4.2 percentage points from the prior year.

Return on Equity
8.0%
YoY-7.7pp
5Y CAGR0.0pp
10Y CAGR-13.6pp

Eastman Chem Co's ROE was 8.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 7.7 percentage points from the prior year.

Operating Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending
$255.0M
YoY+2.0%
5Y CAGR+2.4%
10Y CAGR+0.5%

Eastman Chem Co invested $255.0M in research and development in fiscal year 2025. This represents an increase of 2.0% from the prior year.

Capital Expenditures
$546.0M
YoY-8.8%
5Y CAGR+7.3%
10Y CAGR-1.8%

Eastman Chem Co invested $546.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 8.8% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

EMN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EMN annual income statement
MetricTTMFY25FY24FY23FY22FY21FY20FY19FY18FY17FY16FY15FY14FY13FY12FY11
Revenue$8.9B$8.8B-6.7%$9.4B+1.9%$9.2B-12.9%$10.6B+1.0%$10.5B+23.6%$8.5B-8.6%$9.3B-8.6%$10.2B+6.3%$9.5B+6.0%$9.0B-6.6%$9.6B+1.3%$9.5B+1.9%$9.3B+15.4%$8.1B+12.9%$7.2B
Cost of Revenue$7.1B$6.9B-2.6%$7.1B-0.8%$7.1B-15.3%$8.4B+5.9%$8.0B+22.7%$6.5B-7.7%$7.0B-8.3%$7.7B+6.8%$7.2B+8.0%$6.7B-5.9%$7.1B-3.3%$7.3B+11.1%$6.6B+3.7%$6.3B+13.0%$5.6B
Gross Profit$1.8B$1.8B-19.5%$2.3B+11.1%$2.1B-3.6%$2.1B-14.5%$2.5B+26.6%$2.0B-11.6%$2.2B-9.9%$2.5B+4.9%$2.4B+0.3%$2.4B-8.6%$2.6B+16.2%$2.2B-20.0%$2.8B+57.5%$1.8B+12.3%$1.6B
R&D Expenses$246.0M$255.0M+2.0%$250.0M+4.6%$239.0M-9.5%$264.0M+3.9%$254.0M+12.4%$226.0M-3.4%$234.0M-0.4%$235.0M+3.5%$227.0M+1.8%$223.0M-7.9%$242.0M+6.6%$227.0M+17.6%$193.0M-2.5%$198.0M+24.5%$159.0M
SG&A Expenses$682.0M$658.0M-10.6%$736.0M+1.2%$727.0M+0.1%$726.0M-8.7%$795.0M+21.6%$654.0M-5.4%$691.0M-4.2%$721.0M-1.1%$729.0M+3.1%$707.0M-8.3%$771.0M+2.1%$755.0M+17.1%$645.0M+0.2%$644.0M+33.9%$481.0M
Operating IncomeN/AN/AN/AN/AN/AN/AN/AN/AN/A$1.5B+10.8%$1.4B-0.1%$1.4B+19.1%$1.2B-37.6%$1.9B+132.8%$800.0M-14.6%$937.0M
Interest Expense-$213.0M-$208.0M-4.0%-$200.0M+7.0%-$215.0M-18.1%-$182.0M+8.1%-$198.0M+5.7%-$210.0M+3.7%-$218.0M+7.2%-$235.0M+2.5%-$241.0M+5.5%-$255.0M+3.0%-$263.0M-40.6%-$187.0M-3.9%-$180.0M-25.9%-$143.0M-88.2%-$76.0M
Income Tax$95.0M$93.0M-45.3%$170.0M-11.0%$191.0M+5.5%$181.0M-15.8%$215.0M+424.4%$41.0M-70.7%$140.0M-38.1%$226.0M+328.3%-$99.0M-152.1%$190.0M-30.9%$275.0M+17.0%$235.0M-53.6%$507.0M+146.1%$206.0M-24.8%$274.0M
Net Income$442.0M$474.0M-47.6%$905.0M+1.2%$894.0M+12.7%$793.0M-7.5%$857.0M+79.3%$478.0M-37.0%$759.0M-29.7%$1.1B-22.0%$1.4B+62.1%$854.0M+0.7%$848.0M+12.9%$751.0M-35.5%$1.2B+166.6%$437.0M-32.4%$646.0M
EPS (Diluted)$4.10-46.5%$7.67+2.4%$7.49+18.0%$6.35+1.6%$6.25+78.6%$3.50-36.1%$5.48-27.5%$7.56-20.2%$9.47+64.7%$5.75+1.6%$5.66+13.9%$4.97-33.2%$7.44+153.9%$2.93-35.2%$4.52

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

EMN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EMN annual balance sheet
MetricFY25FY24FY23FY22FY21FY20FY19FY18FY17FY16FY15FY14FY13FY12FY11
Total Assets$14.9B-2.3%$15.2B+4.0%$14.6B-0.2%$14.7B-5.5%$15.5B-3.5%$16.1B+0.5%$16.0B+0.1%$16.0B0.0%$16.0B+3.5%$15.5B-0.8%$15.6B-3.1%$16.1B+35.7%$11.8B+1.2%$11.7B+89.4%$6.2B
Current Assets$3.6B-11.1%$4.1B+17.8%$3.5B-7.9%$3.8B-18.7%$4.6B+31.2%$3.5B+6.6%$3.3B-1.3%$3.4B+7.1%$3.1B+9.7%$2.9B-0.4%$2.9B-9.3%$3.2B+11.7%$2.8B+5.2%$2.7B+17.2%$2.3B
Cash & Equivalents$566.0M-32.4%$837.0M+52.7%$548.0M+11.2%$493.0M+7.4%$459.0M-18.6%$564.0M+176.5%$204.0M-9.7%$226.0M+18.3%$191.0M+5.5%$181.0M-38.2%$293.0M+36.9%$214.0M-9.7%$237.0M-4.8%$249.0M-56.8%$577.0M
Inventory$2.0B-0.4%$2.0B+18.1%$1.7B-11.1%$1.9B+25.9%$1.5B+9.1%$1.4B-17.0%$1.7B+5.0%$1.6B+4.9%$1.5B+7.5%$1.4B-5.1%$1.5B-2.0%$1.5B+19.4%$1.3B+0.3%$1.3B+61.7%$779.0M
Accounts Receivable$737.0M-6.8%$791.0M-4.2%$826.0M-13.7%$957.0M-12.3%$1.1B+5.6%$1.0B+5.4%$980.0M-15.1%$1.2B+12.5%$1.0B+26.4%$812.0M+2.5%$792.0M-15.4%$936.0M+6.4%$880.0M+4.0%$846.0M+33.9%$632.0M
Goodwill$3.7B+0.9%$3.6B-0.4%$3.6B-0.5%$3.7B+0.6%$3.6B-18.5%$4.5B+0.8%$4.4B-0.8%$4.5B-1.3%$4.5B+1.5%$4.5B-1.3%$4.5B+0.7%$4.5B+70.1%$2.6B-0.3%$2.6B+551.2%$406.0M
Total Liabilities$8.8B-5.8%$9.4B+2.8%$9.1B-3.5%$9.4B-3.1%$9.7B-2.4%$10.0B0.0%$10.0B-1.4%$10.1B-3.8%$10.5B-3.0%$10.8B-6.1%$11.6B-7.4%$12.5B+56.6%$8.0B-8.2%$8.7B+102.7%$4.3B
Current Liabilities$2.7B-2.1%$2.7B+5.1%$2.6B-20.8%$3.3B+9.4%$3.0B+45.8%$2.0B+13.9%$1.8B-3.3%$1.9B-6.6%$2.0B+10.4%$1.8B-12.7%$2.1B+1.7%$2.0B+37.6%$1.5B+7.8%$1.4B+22.4%$1.1B
Long-Term Debt$4.2B-8.0%$4.6B+6.1%$4.3B+7.0%$4.0B-8.8%$4.4B-16.3%$5.3B-6.1%$5.6B-5.3%$5.9B-3.6%$6.1B-2.6%$6.3B-4.0%$6.6B-9.3%$7.2B+70.4%$4.3B-11.0%$4.8B+230.7%$1.4B
Total Equity$6.0B+3.1%$5.8B+5.9%$5.5B+5.9%$5.2B-9.7%$5.7B-5.3%$6.0B+1.1%$6.0B+2.7%$5.8B+7.4%$5.4B+19.2%$4.5B+15.0%$3.9B+12.3%$3.5B-7.5%$3.8B+29.0%$2.9B+57.4%$1.9B
Retained Earnings$10.1B+0.9%$10.0B+5.5%$9.5B+5.8%$9.0B+4.9%$8.6B+5.9%$8.1B+1.4%$8.0B+5.2%$7.6B+11.3%$6.8B+18.9%$5.7B+11.2%$5.1B+13.2%$4.5B+13.3%$4.0B+32.1%$3.0B+10.1%$2.8B

EMN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

EMN annual cash flow statement
MetricTTMFY25FY24FY23FY22FY21FY20FY19FY18FY17FY16FY15FY14FY13FY12FY11
Operating Cash Flow$991.0M$970.0M-24.6%$1.3B-6.3%$1.4B+40.9%$975.0M-39.8%$1.6B+11.3%$1.5B-3.3%$1.5B-2.5%$1.5B-6.9%$1.7B+19.6%$1.4B-14.7%$1.6B+13.3%$1.4B+10.5%$1.3B+15.0%$1.1B+80.5%$625.0M
Capital Expenditures$452.0M$546.0M-8.8%$599.0M-27.7%$828.0M+35.5%$611.0M+10.1%$555.0M+44.9%$383.0M-9.9%$425.0M-19.5%$528.0M-18.6%$649.0M+3.7%$626.0M-4.0%$652.0M+9.9%$593.0M+22.8%$483.0M+3.9%$465.0M+1.8%$457.0M
Free Cash Flow$539.0M$424.0M-38.4%$688.0M+26.0%$546.0M+50.0%$364.0M-65.8%$1.1B-0.7%$1.1B-0.6%$1.1B+6.3%$1.0B+0.7%$1.0B+32.8%$759.0M-21.9%$972.0M+15.7%$840.0M+3.2%$814.0M+22.8%$663.0M+294.6%$168.0M
Investing Cash Flow-$387.0M-$462.0M+13.5%-$534.0M-23.6%-$432.0M-210.2%$392.0M+1451.7%-$29.0M+92.6%-$394.0M+17.9%-$480.0M-3.7%-$463.0M+28.0%-$643.0M+1.8%-$655.0M+5.5%-$693.0M+83.1%-$4.1B-795.2%-$457.0M+84.6%-$3.0B-1985.9%-$142.0M
Financing Cash Flow-$342.0M-$797.0M-75.6%-$454.0M+48.9%-$888.0M+32.8%-$1.3B+21.8%-$1.7B-140.1%-$704.0M+32.5%-$1.0B-0.3%-$1.0B-3.4%-$1.0B-20.0%-$838.0M+0.7%-$844.0M-132.0%$2.6B+407.2%-$859.0M-157.1%$1.5B+455.6%-$423.0M
Dividends Paid$382.0M$381.0M+0.5%$379.0M+0.8%$376.0M-1.3%$381.0M+1.6%$375.0M+4.7%$358.0M+4.4%$343.0M+7.9%$318.0M+7.4%$296.0M+8.8%$272.0M+14.3%$238.0M+13.3%$210.0M+50.0%$140.0M-27.1%$192.0M+41.2%$136.0M
Share BuybacksN/AN/AN/AN/AN/A$900.0MN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

EMN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

EMN annual financial ratios
MetricFY25FY24FY23FY22FY21FY20FY19FY18FY17FY16FY15FY14FY13FY12FY11
Gross Margin21.1%-3.3pp24.4%+2.0pp22.4%+2.2pp20.2%-3.7pp23.9%+0.6pp23.3%-0.8pp24.1%-0.3pp24.4%-0.3pp24.8%-1.4pp26.2%-0.6pp26.7%+3.4pp23.3%-6.4pp29.7%+7.9pp21.8%-0.1pp21.9%
Operating MarginN/AN/AN/AN/AN/AN/AN/AN/A16.0%+0.7pp15.3%+1.0pp14.3%+2.1pp12.2%-7.7pp19.9%+10.0pp9.9%-3.2pp13.1%
Net Margin5.4%-4.2pp9.7%-0.1pp9.7%+2.2pp7.5%-0.7pp8.2%+2.5pp5.6%-2.6pp8.2%-2.4pp10.6%-3.9pp14.5%+5.0pp9.5%+0.7pp8.8%+0.9pp7.9%-4.6pp12.5%+7.1pp5.4%-3.6pp9.0%
Return on Equity8.0%-7.7pp15.7%-0.7pp16.4%+1.0pp15.4%+0.4pp15.0%+7.1pp7.9%-4.8pp12.7%-5.9pp18.6%-7.0pp25.6%+6.8pp18.8%-2.7pp21.5%+0.1pp21.4%-9.3pp30.7%+15.8pp14.8%-19.7pp34.5%
Return on Assets3.2%-2.8pp5.9%-0.2pp6.1%+0.7pp5.4%-0.1pp5.5%+2.5pp3.0%-1.8pp4.7%-2.0pp6.8%-1.9pp8.6%+3.1pp5.5%+0.1pp5.4%+0.8pp4.7%-5.2pp9.8%+6.1pp3.7%-6.7pp10.4%
Current Ratio1.37-0.1x1.51+0.2x1.35+0.2x1.16-0.4x1.56-0.2x1.74-0.1x1.860.0x1.82+0.2x1.590.0x1.60+0.2x1.40-0.2x1.57-0.4x1.930.0x1.98-0.1x2.07
Debt-to-Equity0.70-0.1x0.790.0x0.790.0x0.780.0x0.77-0.1x0.87-0.1x0.94-0.1x1.02-0.1x1.14-0.3x1.39-0.3x1.67-0.4x2.06+0.9x1.12-0.5x1.62+0.9x0.77
FCF Margin4.8%-2.5pp7.3%+1.4pp5.9%+2.5pp3.4%-6.7pp10.2%-2.5pp12.7%+1.0pp11.6%+1.6pp10.0%-0.6pp10.6%+2.1pp8.4%-1.6pp10.1%+1.2pp8.8%+0.1pp8.7%+0.5pp8.2%+5.8pp2.3%

Similar Companies

Frequently Asked Questions

What is Eastman Chem Co's annual revenue?

Eastman Chem Co (EMN) reported $8.8B in total revenue for fiscal year 2025. This represents a -6.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Eastman Chem Co's revenue growing?

Eastman Chem Co (EMN) revenue declined by 6.7% year-over-year, from $9.4B to $8.8B in fiscal year 2025.

Is Eastman Chem Co profitable?

Yes, Eastman Chem Co (EMN) reported a net income of $474.0M in fiscal year 2025, with a net profit margin of 5.4%.

Eastman Chem Co (EMN) reported diluted earnings per share of $4.10 for fiscal year 2025. This represents a -46.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

As of fiscal year 2025, Eastman Chem Co (EMN) had $566.0M in cash and equivalents against $4.2B in long-term debt.

Eastman Chem Co (EMN) had a gross margin of 21.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Eastman Chem Co (EMN) had a net profit margin of 5.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Yes, Eastman Chem Co (EMN) paid $3.33 per share in dividends during fiscal year 2025.

Eastman Chem Co (EMN) has a return on equity of 8.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Eastman Chem Co (EMN) generated $424.0M in free cash flow during fiscal year 2025. This represents a -38.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Eastman Chem Co (EMN) generated $970.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Eastman Chem Co (EMN) had $14.9B in total assets as of fiscal year 2025, including both current and long-term assets.

Eastman Chem Co (EMN) invested $546.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Eastman Chem Co (EMN) invested $255.0M in research and development during fiscal year 2025.

Eastman Chem Co (EMN) had 114M shares outstanding as of fiscal year 2025.

Eastman Chem Co (EMN) had a current ratio of 1.37 as of fiscal year 2025, which is considered adequate.

Eastman Chem Co (EMN) had a debt-to-equity ratio of 0.70 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Eastman Chem Co (EMN) had a return on assets of 3.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Eastman Chem Co (EMN) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Eastman Chem Co (EMN) has an earnings quality ratio of 2.05x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Eastman Chem Co (EMN) scores 27 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top